#USA #New York #Gross Law Firm #REGENXBIO #RGNX

RGNX Shareholder Alert: Class Action Lawsuit Overview

Understanding the RGNX Situation

In light of recent events surrounding REGENXBIO Inc. (NASDAQ: RGNX), shareholders have been alerted to their potential rights under securities laws. The Gross Law Firm has issued a notice aimed primarily at those who purchased RGNX shares between February 9, 2022, and January 27, 2026.

The Background of Allegations

The allegations against REGENXBIO center on claims made by the company about their product candidate RGX-111, designed as a one-time gene therapy for treating severe Mucopolysaccharidosis Type I, commonly known as Hurler syndrome. In their communications, the company reportedly expressed strong optimism about RGX-111's trial outcomes based on favorable biomarker responses and safety data observed in ongoing clinical studies. However, alongside these promising declarations, they allegedly omitted critical information regarding the safety and efficacy of the RGX-111 trial. This could constitute a violation of securities laws by misleading investors.

On January 28, 2026, an event shook investor confidence when REGENXBIO disclosed that the FDA had imposed a clinical hold on RGX-111 following the discovery of an intraventricular CNS tumor in a participant. This announcement led to a significant fallout in the company's stock value, which dropped from $13.41 per share to $11.01 in a single trading day—a staggering decline of 17.8%.

Seeking Class Action Leadership

For affected shareholders, there is an urgent call to take action. The Gross Law Firm is seeking individuals who experienced losses to step forward and potentially lead the class action lawsuit. Being appointed as a lead plaintiff isn’t obligatory for participation in any recovery from the proceedings, but it does provide an opportunity for those highly engaged in the case to steer the direction of the claims.

The deadline to register as a lead plaintiff is set for April 14, 2026, which imposes a pressing timeline for those considering their options in light of these serious allegations. The law firm emphasizes that registration is free and there are no obligations imposed on participants. By registering, shareholders will gain access to monitoring tools that will keep them updated on the case's progress, allowing for a more informed participation.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for defending the rights of investors victimized by corporate misconduct. Their commitment focuses on accountability and recovery for clients affected by misleading corporate communications. In light of recent alterations in the information provided by REGENXBIO, those affected can feel assured that the firm is equipped and dedicated to navigating the complexities of securities law and the class action process.

Investors are encouraged to reach out to The Gross Law Firm for further details regarding the registration process or to ask any questions they may have regarding their potential involvement. Given the serious nature of the allegations and the significant financial implications at stake, this becomes a critical moment for shareholders of REGENXBIO.

Next Steps

To get involved, shareholders should visit the link provided in the notice to complete the registration form. The Gross Law Firm remains available for consultations via email or phone for immediate inquiries regarding this matter.

For ongoing updates and support, please ensure you register promptly to ensure your interests are adequately represented.

• ---

For more information, please contact The Gross Law Firm at 15 West 38th Street, 12th floor, New York, NY, 10018. Email: [email protected], Phone: (646) 453-8903.